Although PD-1 antibodies have been widely used in routine clinical practice for R/M HNSCC, there are no clinically available biomarkers other than PD-L1 expression scores; thus, biomarker-guided precision medicine is yet to be realized. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.